MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group
暂无分享,去创建一个
A. Look | A. Naranjo | J. Gastier-Foster | J. Maris | H. Shimada | S. Asgharzadeh | W. London | M. Hogarty | R. Seeger | B. Chiu | N. Ikegaki | S. Cohn | Larry L. Wang | Julie R. Park | Collin Van Ryn | J. Coburn | K. Ornell | Xao X. Tang | Jasmine Zeki | Ryosuke Matsuno | Risa Niemas-Teshiba | Xao X. Tang
[1] K. Alitalo,et al. Oncogene Amplification , 2020, Gene Amplification in Mammalian Cells.
[2] D. Kaplan,et al. Modulation of vincristine and doxorubicin binding and release from silk films. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[3] C. Dang,et al. MYC, Metabolism, and Cancer. , 2015, Cancer discovery.
[4] D. Kaplan,et al. Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo. , 2015, Acta biomaterialia.
[5] A. Look,et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study , 2015, British Journal of Cancer.
[6] G. McArthur,et al. A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM). , 2015 .
[7] R. Eisenman,et al. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. , 2015, Biochimica et biophysica acta.
[8] A. Look,et al. Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group , 2014, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[9] R. Hannan,et al. Targeting RNA polymerase I to treat MYC-driven cancer , 2014, Oncogene.
[10] R. Hannan,et al. The nucleolus: an emerging target for cancer therapy. , 2013, Trends in molecular medicine.
[11] E. Rappaport,et al. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines , 2013, International journal of oncology.
[12] Xiaoping Zhou,et al. Ribosomal Proteins L5 and L11 Cooperatively Inactivate c-Myc via RNA-induced Silencing Complex , 2013, Oncogene.
[13] A. Look,et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group , 2013, Cancer.
[14] C. Dang. MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.
[15] R. Pearson,et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer , 2013, Nature Reviews Cancer.
[16] A. Look,et al. Peripheral neuroblastic tumors with genotype–phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee , 2013, Pediatric blood & cancer.
[17] R. Stallings,et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression , 2012, Nature Genetics.
[18] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[19] Mark S. Sundrud,et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase , 2011, Nature chemical biology.
[20] D. Kaplan,et al. Materials fabrication from Bombyx mori silk fibroin , 2011, Nature Protocols.
[21] R. Hannan,et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.
[22] Gerald Wang,et al. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. , 2010, International journal of oncology.
[23] E. Rappaport,et al. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. , 2010, International Journal of Oncology.
[24] D. Felsher,et al. MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.
[25] Mark S. Sundrud,et al. Halofuginone Inhibits TH17 Cell Differentiation by Activating the Amino Acid Starvation Response , 2009, Science.
[26] Barbara Hero,et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Beijersbergen,et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.
[28] M. Dai,et al. Inhibition of c‐Myc activity by ribosomal protein L11 , 2007, The EMBO journal.
[29] Yanping Zhang,et al. Putting a Finger on Growth Surveillance: Insight into MDM2 Zinc Finger-Ribosomal Protein Interactions , 2007, Cell cycle.
[30] Philip R. Gafken,et al. Myc influences global chromatin structure , 2006, The EMBO journal.
[31] K K Matthay,et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Stram,et al. Revision of the International Neuroblastoma Pathology Classification , 2003, Cancer.
[33] Hiroyuki Shimada,et al. Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groups , 2002, Cancer.
[34] D. Stram,et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors , 2001, Cancer.
[35] D. Stram,et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors , 2001, Cancer.
[36] C. Dang,et al. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] Hiroyuki Shimada,et al. Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.
[38] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[39] S. Cohn,et al. Advances in the diagnosis and treatment of neuroblastoma , 1998, Current opinion in oncology.
[40] L. Robison,et al. Infant Cancer in the U.S.: Histology‐Specific Incidence and Trends, 1973 to 1992 , 1997, Journal of pediatric hematology/oncology.
[41] D. Stram,et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. , 1995, Journal of the National Cancer Institute.
[42] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[43] A T Look,et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Kaneko,et al. Coamplification of the L‐myc and N‐myc Oncogenes in a Neuroblastoma Cell Line , 1989, Japanese journal of cancer research : Gann.
[45] R. Kennett,et al. Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[46] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[47] P. T. Speakman,et al. Isoelectric focusing of silk fibroin polypeptides , 1985 .
[48] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[49] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[50] M. Fischberg,et al. Localization of the ribosomal DNA complements in the nucleolar organizer region of Xenopus laevis. , 1966, National Cancer Institute monograph.
[51] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[52] E. Connolly,et al. Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.